SK Biopharmaceuticals Co., Ltd.
326030
Kedudukan dalam Saham
#4039
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Harga Saham
$51.65
Modal Pasaran
$4.05B
Perubahan (1 hari)
0.27%
Perubahan (1 tahun)
-30.95%
Negara
KR
Perdagangan SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Hasil untuk SK Biopharmaceuticals Co., Ltd. (326030)
Hasil pada Jun 2026 TTM: $595.61M
Menurut laporan kewangan terkini daripada SK Biopharmaceuticals Co., Ltd., hasil semasa syarikat (TTM) ialah $595.61M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $372.47M peningkatan berbanding hasil pada tahun 2023 iaitu $274.15M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi SK Biopharmaceuticals Co., Ltd. dari 2011 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $595.61M | 21.75% |
| 2025 | $489.22M | 31.34% |
| 2024 | $372.47M | 35.86% |
| 2023 | $274.15M | 40.53% |
| 2022 | $195.08M | -44.60% |
| 2021 | $352.13M | 1,370.42% |
| 2020 | $23.95M | -77.67% |
| 2019 | $107.25M | 10,769.59% |
| 2018 | $986.74K | -98.77% |
| 2017 | $80.05M | 7.33% |
| 2016 | $74.58M | 22.73% |
| 2015 | $60.77M | -8.20% |
| 2014 | $66.20M | 15.28% |
| 2013 | $57.42M | 18.01% |
| 2012 | $48.66M | 49.86% |
| 2011 | $32.47M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 2,019.55% |
US
|
|
| $2.23B | 274.07% |
US
|
|
| $15.74B | 2,543.39% |
AU
|
|
| $6.02B | 910.94% |
NL
|
|
| - | - |
CH
|
